Tin tức & Cập nhật
Xem bài viết Đa khoa
Xem
Chỉ hiển thị Multimedia

Nerandomilast slows IPF progression in patients already on antifibrotic therapy
11 Jul 2025
bởiElvira Manzano
The novel oral PDE4B* inhibitor nerandomilast slows the progression of idiopathic pulmonary fibrosis (IPF) in patients receiving antifibrotic treatment, as shown in the phase III FIBRONEER-IPF trial.








